Back to top

Alnylam slips as recent analyst target cuts appear to overshadow pipeline updates ahead of earnings

Alnylam Pharmaceuticals (ALNY) is down 4.2% today. Here is some analysis on what might have caused this price movement. ([itiger.com](https://www.itiger.com/news/2651186441))

Analysis: The most likely driver looks like a cooling-off move after several recent analyst target cuts, even as Alnylam continued to post pipeline progress and set its second-quarter report for July 30. This could also reflect investors resetting expectations for the company’s ATTR franchise and near-term margin outlook after a strong earlier run in the shares. ([investing.com](https://www.investing.com/news/analyst-ratings/bofa-cuts-alnylam-stock-price-target-on-conservative-outlook-93CH-4790387?utm_source=openai))

Details:

  • Alnylam said on July 16 that it will report second-quarter 2026 results before the market opens on July 30 and will host a management call that morning, putting focus on updated commercial commentary and outlook. ([itiger.com](https://www.itiger.com/news/2651186441))
  • On July 15, the company highlighted neuroscience pipeline progress, including the start of a global Phase 2 study of mivelsiran in Down syndrome-associated Alzheimer’s disease and completed enrollment in another Phase 2 mivelsiran study. ([capella.alnylam.com](https://capella.alnylam.com/our-science/capella-rnai-innovation-2?utm_source=openai))
  • BofA recently cut its price target to $410 from $460 while keeping a Buy rating, citing a more conservative long-term view. ([investing.com](https://www.investing.com/news/analyst-ratings/bofa-cuts-alnylam-stock-price-target-on-conservative-outlook-93CH-4790387?utm_source=openai))
  • Truist also reduced its target to $410 from $505, reflecting a more cautious view on ATTR-related assumptions and product mix. ([fr.investing.com](https://fr.investing.com/news/analyst-ratings/truist-abaisse-lobjectif-de-cours-dalnylam-a-410-sur-les-perspectives-attr-93CH-3495823?utm_source=openai))
  • Sources:

    Alnylam, Investing.com, BioSpace

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $ALNY Insider Trading Activity

    ALNY Insider Trades

    $ALNY insiders have traded $ALNY stock on the open market 136 times in the past 6 months. Of those trades, 0 have been purchases and 136 have been sales.

    Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:

    • YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 19 sales selling 16,690 shares for an estimated $5,332,821.
    • PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 32 sales selling 15,074 shares for an estimated $4,883,227.
    • KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 28 sales selling 8,541 shares for an estimated $2,754,438.
    • JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 19 sales selling 6,916 shares for an estimated $2,215,352.
    • TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 19 sales selling 5,866 shares for an estimated $1,877,015.
    • MELISSA MCLAUGHLIN (Chief Human Resources Officer) has made 0 purchases and 14 sales selling 3,910 shares for an estimated $1,274,342.
    • DAVID E I PYOTT has made 0 purchases and 5 sales selling 3,830 shares for an estimated $1,145,852.

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    EARLY ACCESS
    Receive ALNY Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $ALNY Hedge Fund Activity

    We have seen 346 institutional investors add shares of $ALNY stock to their portfolio, and 397 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $ALNY Analyst Ratings

    Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • HC Wainwright & Co. issued a "Buy" rating on 06/29/2026
    • B of A Securities issued a "Buy" rating on 01/30/2026
    • Barclays issued a "Overweight" rating on 01/28/2026

    To track analyst ratings and price targets for $ALNY, check out Quiver Quantitative's $ALNY forecast page.

    $ALNY Price Targets

    Multiple analysts have issued price targets for $ALNY recently. We have seen 13 analysts offer price targets for $ALNY in the last 6 months, with a median target of $429.0.

    Here are some recent targets:

    • Patrick R. Trucchio from HC Wainwright & Co. set a target price of $470.0 on 06/29/2026
    • Eric Joseph from Citigroup set a target price of $380.0 on 05/19/2026
    • Luca Issi from RBC Capital set a target price of $445.0 on 05/01/2026
    • Derek Archila from Wells Fargo set a target price of $377.0 on 05/01/2026
    • Danielle Brill from Truist Securities set a target price of $505.0 on 04/13/2026
    • Keay Nakae from Chardan Capital set a target price of $425.0 on 03/25/2026
    • Faisal Khurshid from Jefferies set a target price of $330.0 on 03/16/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Read full article here »

    In-Depth Zacks Research for the Tickers Above

    Normally $25 each - click below to receive one report FREE:

    Alnylam Pharmaceuticals, Inc. (ALNY)